perampanel 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antagonists of the ionotropic non-NMDA (N-methyl-D-aspartate) glutamate receptors (Namely the AMPA (amino-hydroxymethyl-isoxazole-propionic acid) and/or KA (kainite antagonist) receptors) 4684 380917-97-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • perampanel hydrate
  • perampanel
  • fycompa
  • E2007
  • E-2007
a non-competitive AMPA glutamate receptor antagonist indicated as adjunctive therapy for the treatment of seizures
  • Molecular weight: 349.39
  • Formula: C23H15N3O
  • CLOGP: 3.87
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 0
  • TPSA: 56.99
  • ALOGS: -4.80
  • ROTB: 3

  • Status: ONP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
8 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Hosey CM, Chan R, Benet LZ
Vd (Volume of distribution) 1.36 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 0.10 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.05 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 183 hours Lombardo F, Berellini G, Obach RS
BA (Bioavailability) 1 % Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K

Approvals:

DateAgencyCompanyOrphan
Jan. 23, 2020 PMDA Eisai Co., Ltd.
Oct. 22, 2012 FDA EISAI INC
July 23, 2012 EMA EISAI GMBH

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Aggression 413.69 38.06 124 4380 23374 63461144
Multiple-drug resistance 314.38 38.06 73 4431 5097 63479421
Status epilepticus 292.29 38.06 86 4418 15147 63469371
Seizure 282.59 38.06 152 4352 132482 63352036
Irritability 205.09 38.06 79 4425 31615 63452903
Drug resistance 165.74 38.06 62 4442 22871 63461647
Suicidal ideation 128.14 38.06 70 4434 62351 63422167
Drug ineffective 124.15 38.06 244 4260 1044521 62439997
Epilepsy 95.92 38.06 44 4460 27021 63457497
Drug interaction 95.07 38.06 98 4406 229033 63255485
Suicide attempt 94.66 38.06 57 4447 60861 63423657
Psychotic disorder 91.74 38.06 42 4462 25670 63458848
Intentional overdose 86.78 38.06 58 4446 74094 63410424
Abnormal behaviour 85.99 38.06 38 4466 21388 63463130
Dizziness 79.98 38.06 123 4381 429802 63054716
Somnolence 78.72 38.06 79 4425 178606 63305912
Agitation 77.86 38.06 50 4454 59707 63424811
Anticonvulsant drug level increased 74.30 38.06 18 4486 1499 63483019
Mood altered 65.17 38.06 28 4476 14715 63469803
Ataxia 61.11 38.06 27 4477 15168 63469350
Generalised tonic-clonic seizure 60.73 38.06 33 4471 28983 63455535
Anger 56.19 38.06 24 4480 12432 63472086
Altered state of consciousness 53.64 38.06 29 4475 25201 63459317
Myoclonic epilepsy 42.09 38.06 11 4493 1243 63483275
Off label use 41.62 38.06 123 4381 674339 62810179
Drug withdrawal convulsions 40.70 38.06 11 4493 1414 63483104
Lipids abnormal 39.65 38.06 8 4496 285 63484233
Partial seizures 39.27 38.06 15 4489 5827 63478691

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Aggression 561.00 39.64 202 4143 38762 34913824
Status epilepticus 272.92 39.64 89 4256 12525 34940061
Seizure 239.15 39.64 153 4192 104704 34847882
Multiple-drug resistance 212.46 39.64 60 4285 5179 34947407
Suicide attempt 166.70 39.64 86 4259 39030 34913556
Irritability 133.90 39.64 64 4281 24626 34927960
Epilepsy 132.88 39.64 61 4284 21434 34931152
Anger 127.85 39.64 50 4295 11834 34940752
Drug ineffective 120.23 39.64 207 4138 456544 34496042
Somnolence 104.73 39.64 96 4249 111020 34841566
Anticonvulsant drug level above therapeutic 89.40 39.64 20 4325 662 34951924
Excessive eye blinking 87.72 39.64 19 4326 540 34952046
Intentional overdose 87.53 39.64 59 4286 43615 34908971
Partial seizures 84.56 39.64 29 4316 4731 34947855
Homicidal ideation 79.04 39.64 24 4321 2658 34949928
Suicidal ideation 74.84 39.64 52 4293 40336 34912250
Gaze palsy 66.60 39.64 19 4326 1693 34950893
Pneumonia aspiration 66.27 39.64 49 4296 41854 34910732
Psychotic disorder 63.71 39.64 39 4306 24413 34928173
Posture abnormal 61.57 39.64 19 4326 2220 34950366
Agitation 60.66 39.64 53 4292 57346 34895240
Generalised tonic-clonic seizure 53.19 39.64 33 4312 21141 34931445
Abnormal behaviour 53.02 39.64 35 4310 24934 34927652
Focal dyscognitive seizures 52.25 39.64 15 4330 1366 34951220
Ataxia 49.11 39.64 27 4318 13826 34938760
Behaviour disorder 46.98 39.64 19 4326 4891 34947695
Sudden unexplained death in epilepsy 41.33 39.64 10 4335 468 34952118
Drug withdrawal convulsions 41.05 39.64 12 4333 1165 34951421

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Aggression 849.84 30.24 280 7747 50678 79685683
Status epilepticus 458.61 30.24 148 7879 24893 79711468
Seizure 437.50 30.24 258 7769 188576 79547785
Multiple-drug resistance 431.61 30.24 112 7915 8696 79727665
Irritability 255.58 30.24 110 7917 41034 79695327
Suicide attempt 230.69 30.24 128 7899 82804 79653557
Drug ineffective 212.61 30.24 383 7644 1080530 78655831
Epilepsy 204.76 30.24 94 7933 40766 79695595
Suicidal ideation 175.21 30.24 104 7923 76236 79660125
Intentional overdose 162.67 30.24 112 7915 105848 79630513
Somnolence 155.16 30.24 153 7874 238828 79497533
Anger 151.25 30.24 59 7968 17103 79719258
Agitation 126.76 30.24 94 7933 99621 79636740
Drug resistance 119.52 30.24 66 7961 42147 79694214
Drug interaction 115.64 30.24 173 7854 415010 79321351
Abnormal behaviour 111.58 30.24 60 7967 36361 79700000
Partial seizures 108.82 30.24 39 7988 8939 79727422
Psychotic disorder 104.38 30.24 60 7967 41342 79695019
Generalised tonic-clonic seizure 98.50 30.24 59 7968 43851 79692510
Ataxia 96.10 30.24 48 7979 24991 79711370
Anticonvulsant drug level increased 88.79 30.24 25 8002 2628 79733733
Anticonvulsant drug level above therapeutic 82.82 30.24 20 8007 1151 79735210
Excessive eye blinking 80.19 30.24 21 8006 1680 79734681
Petit mal epilepsy 77.48 30.24 27 8000 5700 79730661
Dizziness 72.77 30.24 162 7865 526279 79210082
Altered state of consciousness 71.11 30.24 48 7979 43774 79692587
Focal dyscognitive seizures 69.26 30.24 22 8005 3490 79732871
Pneumonia aspiration 67.34 30.24 55 7972 66912 79669449
Gaze palsy 64.16 30.24 20 8007 2985 79733376
Sudden unexplained death in epilepsy 60.82 30.24 14 8013 654 79735707
Drug withdrawal convulsions 56.88 30.24 17 8010 2203 79734158
Seizure cluster 56.36 30.24 12 8015 390 79735971
Hostility 56.21 30.24 17 8010 2293 79734068
Posture abnormal 55.29 30.24 19 8008 3847 79732514
Hyperammonaemia 53.87 30.24 25 8002 11068 79725293
Homicidal ideation 53.40 30.24 18 8009 3439 79732922
Product administered to patient of inappropriate age 52.13 30.24 20 8007 5533 79730828
Mood altered 50.74 30.24 28 7999 17819 79718542
Pain 50.30 30.24 6 8021 703796 79032565
Off label use 48.86 30.24 200 7827 907015 78829346
Behaviour disorder 46.22 30.24 19 8008 6294 79730067
Dyspnoea 45.35 30.24 15 8012 857010 78879351
Hyperammonaemic encephalopathy 44.09 30.24 17 8010 4765 79731596
Hallucination, auditory 36.78 30.24 24 8003 20669 79715692
Drug level decreased 36.61 30.24 21 8006 14381 79721980
Physical assault 35.56 30.24 11 8016 1600 79734761
Partial seizures with secondary generalisation 35.51 30.24 9 8018 632 79735729
Malaise 35.39 30.24 4 8023 489865 79246496
Cognitive disorder 34.88 30.24 39 7988 69887 79666474
Haematuria traumatic 34.09 30.24 7 8020 190 79736171
Arthralgia 33.92 30.24 8 8019 571795 79164566
Diarrhoea 33.54 30.24 24 8003 880465 78855896
Craniocerebral injury 32.56 30.24 14 8013 5182 79731179
Lipids abnormal 30.88 30.24 8 8019 613 79735748

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N03AX22 NERVOUS SYSTEM
ANTIEPILEPTICS
ANTIEPILEPTICS
Other antiepileptics
FDA MoA N0000020016 AMPA Receptor Antagonists
FDA MoA N0000182141 Cytochrome P450 3A4 Inhibitors
FDA EPC N0000186106 Noncompetitive AMPA Glutamate Receptor Antagonist
FDA MoA N0000187062 Cytochrome P450 2C8 Inhibitors
FDA MoA N0000191273 UGT2B7 Inhibitors
FDA MoA N0000191278 UGT1A9 Inhibitors
CHEBI has role CHEBI:35623 anticonvulsants
CHEBI has role CHEBI:71014 alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonists

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Secondarily generalized seizures indication 20544001
Partial seizure indication 29753000
Idiopathic generalized epilepsy indication 36803009




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 3.89 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
10MG FYCOMPA CATALYST PHARMS N202834 Oct. 22, 2012 RX TABLET ORAL 6949571 June 8, 2024 TREATMENT OF EPILEPSY
10MG FYCOMPA CATALYST PHARMS N202834 Oct. 22, 2012 RX TABLET ORAL 6949571 June 8, 2024 TREATMENT OF PARTIAL-ONSET SEIZURES WITH OR WITHOUT SECONDARILY GENERALIZED SEIZURES IN PATIENTS WITH EPILEPSY
10MG FYCOMPA CATALYST PHARMS N202834 Oct. 22, 2012 RX TABLET ORAL 6949571 June 8, 2024 TREATMENT OF PARTIAL-ONSET SEIZURES WITH OR WITHOUT SECONDARILY GENERALIZED SEIZURES IN PATIENTS WITH EPILEPSY 4 YEARS OF AGE AND OLDER
10MG FYCOMPA CATALYST PHARMS N202834 Oct. 22, 2012 RX TABLET ORAL 6949571 June 8, 2024 TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES AS ADJUNCTIVE THERAPY IN PATIENTS WITH EPILEPSY
10MG FYCOMPA CATALYST PHARMS N202834 Oct. 22, 2012 RX TABLET ORAL 6949571 June 8, 2024 TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES AS ADJUNCTIVE THERAPY IN PATIENTS WITH EPILEPSY 12 YEARS OF AGE AND OLDER
12MG FYCOMPA CATALYST PHARMS N202834 Oct. 22, 2012 RX TABLET ORAL 6949571 June 8, 2024 TREATMENT OF EPILEPSY
12MG FYCOMPA CATALYST PHARMS N202834 Oct. 22, 2012 RX TABLET ORAL 6949571 June 8, 2024 TREATMENT OF PARTIAL-ONSET SEIZURES WITH OR WITHOUT SECONDARILY GENERALIZED SEIZURES IN PATIENTS WITH EPILEPSY
12MG FYCOMPA CATALYST PHARMS N202834 Oct. 22, 2012 RX TABLET ORAL 6949571 June 8, 2024 TREATMENT OF PARTIAL-ONSET SEIZURES WITH OR WITHOUT SECONDARILY GENERALIZED SEIZURES IN PATIENTS WITH EPILEPSY 4 YEARS OF AGE AND OLDER
12MG FYCOMPA CATALYST PHARMS N202834 Oct. 22, 2012 RX TABLET ORAL 6949571 June 8, 2024 TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES AS ADJUNCTIVE THERAPY IN PATIENTS WITH EPILEPSY
12MG FYCOMPA CATALYST PHARMS N202834 Oct. 22, 2012 RX TABLET ORAL 6949571 June 8, 2024 TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES AS ADJUNCTIVE THERAPY IN PATIENTS WITH EPILEPSY 12 YEARS OF AGE AND OLDER
2MG FYCOMPA CATALYST PHARMS N202834 Oct. 22, 2012 RX TABLET ORAL 6949571 June 8, 2024 TREATMENT OF EPILEPSY
2MG FYCOMPA CATALYST PHARMS N202834 Oct. 22, 2012 RX TABLET ORAL 6949571 June 8, 2024 TREATMENT OF PARTIAL-ONSET SEIZURES WITH OR WITHOUT SECONDARILY GENERALIZED SEIZURES IN PATIENTS WITH EPILEPSY
2MG FYCOMPA CATALYST PHARMS N202834 Oct. 22, 2012 RX TABLET ORAL 6949571 June 8, 2024 TREATMENT OF PARTIAL-ONSET SEIZURES WITH OR WITHOUT SECONDARILY GENERALIZED SEIZURES IN PATIENTS WITH EPILEPSY 4 YEARS OF AGE AND OLDER
2MG FYCOMPA CATALYST PHARMS N202834 Oct. 22, 2012 RX TABLET ORAL 6949571 June 8, 2024 TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES AS ADJUNCTIVE THERAPY IN PATIENTS WITH EPILEPSY
2MG FYCOMPA CATALYST PHARMS N202834 Oct. 22, 2012 RX TABLET ORAL 6949571 June 8, 2024 TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES AS ADJUNCTIVE THERAPY IN PATIENTS WITH EPILEPSY 12 YEARS OF AGE AND OLDER
4MG FYCOMPA CATALYST PHARMS N202834 Oct. 22, 2012 RX TABLET ORAL 6949571 June 8, 2024 TREATMENT OF EPILEPSY
4MG FYCOMPA CATALYST PHARMS N202834 Oct. 22, 2012 RX TABLET ORAL 6949571 June 8, 2024 TREATMENT OF PARTIAL-ONSET SEIZURES WITH OR WITHOUT SECONDARILY GENERALIZED SEIZURES IN PATIENTS WITH EPILEPSY
4MG FYCOMPA CATALYST PHARMS N202834 Oct. 22, 2012 RX TABLET ORAL 6949571 June 8, 2024 TREATMENT OF PARTIAL-ONSET SEIZURES WITH OR WITHOUT SECONDARILY GENERALIZED SEIZURES IN PATIENTS WITH EPILEPSY 4 YEARS OF AGE AND OLDER
4MG FYCOMPA CATALYST PHARMS N202834 Oct. 22, 2012 RX TABLET ORAL 6949571 June 8, 2024 TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES AS ADJUNCTIVE THERAPY IN PATIENTS WITH EPILEPSY
4MG FYCOMPA CATALYST PHARMS N202834 Oct. 22, 2012 RX TABLET ORAL 6949571 June 8, 2024 TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES AS ADJUNCTIVE THERAPY IN PATIENTS WITH EPILEPSY 12 YEARS OF AGE AND OLDER
6MG FYCOMPA CATALYST PHARMS N202834 Oct. 22, 2012 RX TABLET ORAL 6949571 June 8, 2024 TREATMENT OF EPILEPSY
6MG FYCOMPA CATALYST PHARMS N202834 Oct. 22, 2012 RX TABLET ORAL 6949571 June 8, 2024 TREATMENT OF PARTIAL-ONSET SEIZURES WITH OR WITHOUT SECONDARILY GENERALIZED SEIZURES IN PATIENTS WITH EPILEPSY
6MG FYCOMPA CATALYST PHARMS N202834 Oct. 22, 2012 RX TABLET ORAL 6949571 June 8, 2024 TREATMENT OF PARTIAL-ONSET SEIZURES WITH OR WITHOUT SECONDARILY GENERALIZED SEIZURES IN PATIENTS WITH EPILEPSY 4 YEARS OF AGE AND OLDER
6MG FYCOMPA CATALYST PHARMS N202834 Oct. 22, 2012 RX TABLET ORAL 6949571 June 8, 2024 TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES AS ADJUNCTIVE THERAPY IN PATIENTS WITH EPILEPSY
6MG FYCOMPA CATALYST PHARMS N202834 Oct. 22, 2012 RX TABLET ORAL 6949571 June 8, 2024 TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES AS ADJUNCTIVE THERAPY IN PATIENTS WITH EPILEPSY 12 YEARS OF AGE AND OLDER
8MG FYCOMPA CATALYST PHARMS N202834 Oct. 22, 2012 RX TABLET ORAL 6949571 June 8, 2024 TREATMENT OF EPILEPSY
8MG FYCOMPA CATALYST PHARMS N202834 Oct. 22, 2012 RX TABLET ORAL 6949571 June 8, 2024 TREATMENT OF PARTIAL-ONSET SEIZURES WITH OR WITHOUT SECONDARILY GENERALIZED SEIZURES IN PATIENTS WITH EPILEPSY
8MG FYCOMPA CATALYST PHARMS N202834 Oct. 22, 2012 RX TABLET ORAL 6949571 June 8, 2024 TREATMENT OF PARTIAL-ONSET SEIZURES WITH OR WITHOUT SECONDARILY GENERALIZED SEIZURES IN PATIENTS WITH EPILEPSY 4 YEARS OF AGE AND OLDER
8MG FYCOMPA CATALYST PHARMS N202834 Oct. 22, 2012 RX TABLET ORAL 6949571 June 8, 2024 TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES AS ADJUNCTIVE THERAPY IN PATIENTS WITH EPILEPSY
8MG FYCOMPA CATALYST PHARMS N202834 Oct. 22, 2012 RX TABLET ORAL 6949571 June 8, 2024 TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES AS ADJUNCTIVE THERAPY IN PATIENTS WITH EPILEPSY 12 YEARS OF AGE AND OLDER
0.5MG/ML FYCOMPA CATALYST PHARMS N208277 April 29, 2016 RX SUSPENSION ORAL 6949571 June 8, 2024 TREATMENT OF EPILEPSY
0.5MG/ML FYCOMPA CATALYST PHARMS N208277 April 29, 2016 RX SUSPENSION ORAL 6949571 June 8, 2024 TREATMENT OF PARTIAL-ONSET SEIZURES WITH OR WITHOUT SECONDARILY GENERALIZED SEIZURES IN PATIENTS WITH EPILEPSY
0.5MG/ML FYCOMPA CATALYST PHARMS N208277 April 29, 2016 RX SUSPENSION ORAL 6949571 June 8, 2024 TREATMENT OF PARTIAL-ONSET SEIZURES WITH OR WITHOUT SECONDARILY GENERALIZED SEIZURES IN PATIENTS WITH EPILEPSY 4 YEARS OF AGE AND OLDER
0.5MG/ML FYCOMPA CATALYST PHARMS N208277 April 29, 2016 RX SUSPENSION ORAL 6949571 June 8, 2024 TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES AS ADJUNCTIVE THERAPY IN PATIENTS WITH EPILEPSY
0.5MG/ML FYCOMPA CATALYST PHARMS N208277 April 29, 2016 RX SUSPENSION ORAL 6949571 June 8, 2024 TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES AS ADJUNCTIVE THERAPY IN PATIENTS WITH EPILEPSY 12 YEARS OF AGE AND OLDER

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Glutamate receptor ionotropic AMPA Ion channel ANTAGONIST IC50 6.61 CHEMBL CHEMBL

External reference:

IDSource
D08964 KEGG_DRUG
4032964 VUID
N0000189940 NUI
4032964 VANDF
CHEBI:71013 CHEBI
6ZP PDB_CHEM_ID
CHEMBL1214124 ChEMBL_ID
C551441 MESH_SUPPLEMENTAL_RECORD_UI
7050 IUPHAR_LIGAND_ID
8834 INN_ID
DB08883 DRUGBANK_ID
H821664NPK UNII
1356552 RXNORM
192918 MMSL
28817 MMSL
d07904 MMSL
014644 NDDF
703127006 SNOMEDCT_US
703728005 SNOMEDCT_US
C2698764 UMLSCUI
9924495 PUBCHEM_CID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Fycompa HUMAN PRESCRIPTION DRUG LABEL 1 62856-272 TABLET 2 mg ORAL NDA 37 sections
Fycompa HUMAN PRESCRIPTION DRUG LABEL 1 62856-272 TABLET 2 mg ORAL NDA 37 sections
Fycompa HUMAN PRESCRIPTION DRUG LABEL 1 62856-274 TABLET 4 mg ORAL NDA 37 sections
Fycompa HUMAN PRESCRIPTION DRUG LABEL 1 62856-274 TABLET 4 mg ORAL NDA 37 sections
Fycompa HUMAN PRESCRIPTION DRUG LABEL 1 62856-276 TABLET 6 mg ORAL NDA 37 sections
Fycompa HUMAN PRESCRIPTION DRUG LABEL 1 62856-276 TABLET 6 mg ORAL NDA 37 sections
Fycompa HUMAN PRESCRIPTION DRUG LABEL 1 62856-278 TABLET 8 mg ORAL NDA 37 sections
Fycompa HUMAN PRESCRIPTION DRUG LABEL 1 62856-278 TABLET 8 mg ORAL NDA 37 sections
Fycompa HUMAN PRESCRIPTION DRUG LABEL 1 62856-280 TABLET 10 mg ORAL NDA 37 sections
Fycompa HUMAN PRESCRIPTION DRUG LABEL 1 62856-280 TABLET 10 mg ORAL NDA 37 sections
Fycompa HUMAN PRESCRIPTION DRUG LABEL 1 62856-282 TABLET 12 mg ORAL NDA 37 sections
Fycompa HUMAN PRESCRIPTION DRUG LABEL 1 62856-282 TABLET 12 mg ORAL NDA 37 sections
Fycompa HUMAN PRESCRIPTION DRUG LABEL 1 62856-290 SUSPENSION 0.50 mg ORAL NDA 37 sections
Fycompa HUMAN PRESCRIPTION DRUG LABEL 1 62856-290 SUSPENSION 0.50 mg ORAL NDA 37 sections
Fycompa HUMAN PRESCRIPTION DRUG LABEL 1 69616-272 TABLET 2 mg ORAL NDA 21 sections
Fycompa HUMAN PRESCRIPTION DRUG LABEL 1 69616-274 TABLET 4 mg ORAL NDA 21 sections
Fycompa HUMAN PRESCRIPTION DRUG LABEL 1 69616-276 TABLET 6 mg ORAL NDA 21 sections
Fycompa HUMAN PRESCRIPTION DRUG LABEL 1 69616-278 TABLET 8 mg ORAL NDA 21 sections
Fycompa HUMAN PRESCRIPTION DRUG LABEL 1 69616-280 TABLET 10 mg ORAL NDA 21 sections
Fycompa HUMAN PRESCRIPTION DRUG LABEL 1 69616-282 TABLET 12 mg ORAL NDA 21 sections
Fycompa HUMAN PRESCRIPTION DRUG LABEL 1 69616-290 SUSPENSION 0.50 mg ORAL NDA 21 sections